<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00947752</url>
  </required_header>
  <id_info>
    <org_study_id>PM033</org_study_id>
    <nct_id>NCT00947752</nct_id>
  </id_info>
  <brief_title>Safety of New Formulation of Glatiramer Acetate</brief_title>
  <acronym>Song</acronym>
  <official_title>An Open-Label, Multicenter, Randomized Study Evaluating the Tolerability and Safety of Two Formulations of Glatiramer Acetate (GA) for Subcutaneous Injection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceutical Industries</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare pain associated with injections and injection-site
      reactions of the approved formulation of Glatiramer Acetate (GA) versus investigational
      formulation of GA. In addition, the investigators will evaluate the side effects of the two
      formulations of GA.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subject-reported Pain Associated Immediately After Each Injection</measure>
    <time_frame>5 weeks of injections</time_frame>
    <description>A visual analog scale (VAS) was used for subjective characteristics that cannot be directly measured. Respondents specified their level of agreement to a statement by indicating a position along a continuous line between two end-points. The VAS scale used 0 mm to represent &quot;no pain&quot; and up to 100 mm to represent &quot;worst possible pain;&quot; subjects drew a continuous line to represent their level of pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Degree of Pain Within 5 Mins After Injection</measure>
    <time_frame>5 weeks of injections</time_frame>
    <description>A visual analog scale (VAS) was used for subjective characteristics that cannot be directly measured. Respondents specified their level of agreement to a statement by indicating a position along a continuous line between two end-points. The VAS scale used 0 mm to represent &quot;no pain&quot; and up to 100 mm to represent &quot;worst possible pain;&quot; subjects drew a continuous line to represent their level of pain.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">147</enrollment>
  <condition>Relapsing Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>F1 Glatiramer acetate 20mg/1.0ml</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>F2 Glatiramer acetate 20mg/0.5ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glatiramer Acetate</intervention_name>
    <description>Subjects received both doses once daily in a crossover fashion, for a total treatment duration of five weeks, including a one-week run-in period. Subject-reported injection pain was recorded in a daily diary.</description>
    <arm_group_label>F1 Glatiramer acetate 20mg/1.0ml</arm_group_label>
    <other_name>F1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental Glatiramer Acetate</intervention_name>
    <description>GA 20 mg/0.5 mL</description>
    <arm_group_label>F2 Glatiramer acetate 20mg/0.5ml</arm_group_label>
    <other_name>F2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects ≥ 18 years of age with a diagnosis of RRMS

          -  Currently injecting GA 20mg/1.0mL per day subcutaneously (SC) for a minimum of 90 days
             utilizing the autoject®2 for glass syringe or by a manual injection technique

          -  Willing to switch from autoject®2 for glass syringe to manual injection technique or
             continue with a manual injection technique during the course of the study

          -  Willing and able to be trained on a seven site injection rotation. Subject must be
             willing to comply with a minimum five injection site rotation plan during the study

          -  Willing and able to complete all procedures and evaluations related to the study

          -  Willing to continue to follow usual injection site preparation and routine adjunctive
             LISR management techniques

          -  Willing and able to provide written informed consent

        Exclusion Criteria:

          -  Currently using or treated with another immunomodulating therapy (IMT) in conjunction
             with GA in the 30 days prior to screening for this study

          -  Currently using intermittent or pulse courses of corticosteroids by any route of
             administration in the 30 days prior to screening for this study. (Corticosteroids are
             prohibited for the duration of the study.)

          -  Currently using an investigational drug or using treatment with any other
             investigational agent in the 30 days prior to screening for this study

          -  Presence or history of skin necrosis

          -  Known extensive dermatological condition that could be a confounding factor

          -  Pregnant or planning pregnancy or breastfeeding

          -  Any physical condition that impairs ability to be injected at the minimum of five
             sites rotation

          -  Not able or willing to complete a daily diary

          -  Use of any other parenteral medications (e.g., intramuscular, SC, intravenous, etc.)
             either currently or in the past 30 days prior to screening for this study

          -  Any other medical or psychiatric conditions that would make the subject unsuitable for
             this research, as determined by the Investigator

          -  Previous participation in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tom Smith, MD</last_name>
    <role>Study Director</role>
    <affiliation>Teva Neuroscience, Inc.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://en.wikipedia.org/wiki/Visual_analogue_scale</url>
    <description>Visual Analog Scale definition</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2009</study_first_submitted>
  <study_first_submitted_qc>July 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2009</study_first_posted>
  <results_first_submitted>September 28, 2010</results_first_submitted>
  <results_first_submitted_qc>May 10, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 9, 2011</results_first_posted>
  <last_update_submitted>February 2, 2017</last_update_submitted>
  <last_update_submitted_qc>February 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Relapsing Remitting Multiple Sclerosis (RRMS)</keyword>
  <keyword>Glatiramer Acetate (GA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glatiramer Acetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were randomly assigned in a 1:1 assignment ratio to one of two drug sequences. Subjects were to manually inject GA (F1 or F2) once daily for 14 days then cross-over to the other formulation for another 14 days of treatment, including a 7-day run-in period on F1 treatment for all participants to assess daily diary compliance.</recruitment_details>
      <pre_assignment_details>To ensure the standardization, all study sites were instructed to train subjects to complete the daily diary, with special attention to the Visual Analog Scale (VAS) used to measure pain.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>F1 Glatiramer Acetate 20mg/1.0ml</title>
        </group>
        <group group_id="P2">
          <title>F2 Glatiramer Acetate 20mg/0.5ml</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>7-Day Run-in Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="147">All subjects started with a daily does of F1 for 7 days</participants>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>1st 14-day Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Crossover to 2nd 14-day Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>F1 Glatiramer Acetate (GA) 20mg/1.0ml</title>
        </group>
        <group group_id="B2">
          <title>F2 Glatiramer Acetate 20mg/0.5ml</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="76"/>
            <count group_id="B2" value="71"/>
            <count group_id="B3" value="147"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="144"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.1" spread="10.64"/>
                    <measurement group_id="B2" value="46.9" spread="9.64"/>
                    <measurement group_id="B3" value="46.0" spread="10.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subject-reported Pain Associated Immediately After Each Injection</title>
        <description>A visual analog scale (VAS) was used for subjective characteristics that cannot be directly measured. Respondents specified their level of agreement to a statement by indicating a position along a continuous line between two end-points. The VAS scale used 0 mm to represent “no pain” and up to 100 mm to represent “worst possible pain;” subjects drew a continuous line to represent their level of pain.</description>
        <time_frame>5 weeks of injections</time_frame>
        <population>Of the 147 subjects to be analyzed, 3 were excluded for discontinuations due to withdraw of consent.</population>
        <group_list>
          <group group_id="O1">
            <title>F1 Glatiramer Acetate (GA) 20mg/1.0ml</title>
          </group>
          <group group_id="O2">
            <title>F2 Glatiramer Acetate 20mg/0.5ml</title>
          </group>
        </group_list>
        <measure>
          <title>Subject-reported Pain Associated Immediately After Each Injection</title>
          <description>A visual analog scale (VAS) was used for subjective characteristics that cannot be directly measured. Respondents specified their level of agreement to a statement by indicating a position along a continuous line between two end-points. The VAS scale used 0 mm to represent “no pain” and up to 100 mm to represent “worst possible pain;” subjects drew a continuous line to represent their level of pain.</description>
          <population>Of the 147 subjects to be analyzed, 3 were excluded for discontinuations due to withdraw of consent.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.89" spread="14.325"/>
                    <measurement group_id="O2" value="8.64" spread="10.825"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Degree of Pain Within 5 Mins After Injection</title>
        <description>A visual analog scale (VAS) was used for subjective characteristics that cannot be directly measured. Respondents specified their level of agreement to a statement by indicating a position along a continuous line between two end-points. The VAS scale used 0 mm to represent “no pain” and up to 100 mm to represent “worst possible pain;” subjects drew a continuous line to represent their level of pain.</description>
        <time_frame>5 weeks of injections</time_frame>
        <population>Of the 147 subjects to be analyzed, 3 were excluded for discontinuations due to withdraw of consent.</population>
        <group_list>
          <group group_id="O1">
            <title>F1 Glatiramer Acetate (GA) 20mg/1.0ml</title>
          </group>
          <group group_id="O2">
            <title>F2 Glatiramer Acetate 20mg/0.5ml</title>
          </group>
        </group_list>
        <measure>
          <title>Degree of Pain Within 5 Mins After Injection</title>
          <description>A visual analog scale (VAS) was used for subjective characteristics that cannot be directly measured. Respondents specified their level of agreement to a statement by indicating a position along a continuous line between two end-points. The VAS scale used 0 mm to represent “no pain” and up to 100 mm to represent “worst possible pain;” subjects drew a continuous line to represent their level of pain.</description>
          <population>Of the 147 subjects to be analyzed, 3 were excluded for discontinuations due to withdraw of consent.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.19" spread="18.583"/>
                    <measurement group_id="O2" value="11.85" spread="14.112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>F1 Glatiramer Acetate (GA) 20mg/1.0ml</title>
        </group>
        <group group_id="E2">
          <title>F2 Glatiramer Acetate 20mg/0.5ml</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor’s review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor’s designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Blinding in this study was not possible due to the subjects' ability to detect difference in the volume of each formulation. The lack of blinding was a known limitation.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Thomas Smith, MD, VP, Medical Affairs</name_or_title>
      <organization>Teva Neuroscience, Inc.</organization>
      <phone>816-508-5000</phone>
      <email>tom.smith@tevapharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

